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ABSTRACT
The expression of Piwi-interacting RNAs, small RNAs that bind to PIWI proteins, 
was until recently believed to be limited to germinal stem cells. We have studied the 
expression of PIWI genes during human lung embryogenesis and in paired tumor 
and normal tissue prospectively collected from 71 resected non-small-cell lung cancer 
patients. The mRNA expression analysis showed that PIWIL1 was highly expressed in 
7-week embryos and downregulated during the subsequent weeks of development. 
PIWIL1 was expressed in 11 of the tumor samples but in none of the normal tissue 
samples. These results were validated by immunohistochemistry, showing faint 
cytoplasmic reactivity in the PIWIL1-positive samples. Interestingly, the patients 
expressing PIWIL1 had a shorter time to relapse (TTR) (p = 0.006) and overall 
survival (OS) (p = 0.0076) than those without PIWIL1 expression. PIWIL2 and 4 were 
downregulated in tumor tissue in comparison to the normal tissue (p < 0.001) and the 
patients with lower levels of PIWIL4 had shorter TTR (p = 0.048) and OS (p = 0.033). 
In the multivariate analysis, PIWIL1 expression emerged as an independent prognostic 
marker. Using 5-Aza-dC treatment and bisulfite sequencing, we observed that PIWIL1 
expression could be regulated in part by methylation. Finally, an in silico study identified 
a stem-cell expression signature associated with PIWIL1 expression.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) accounts 
for 85% of all lung cancers and has a 5-year survival 
rate of 16% [1]. Surgery is the initial treatment for early-
stage NSCLC patients, but even after complete resection, 
recurrence rates are substantial (20–85%, depending on 
tumor stage) [2], highlighting the need for prognostic 
markers. From a stem-cell point of view, a tumor can be 
viewed as an aberrant organ initiated by a tumorigenic 
cancer cell that acquires the capacity for indefinite 
proliferation through accumulated mutations [3], indicating 
that the study of embryogenesis can be a good source of 
prognostic markers. Several studies have shown that cancer 
recapitulates the gene expression pattern found in the early 
development of the corresponding organ [4–7] and genes 
that are functionally altered in lung cancer, including non-
coding RNA genes, play a key role in lung development [8].
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The recognition of the importance of non-coding 
RNAs in cancer biology has increased considerably in 
recent years, with a special focus on small non-coding 
RNAs (<200bp long) [9]. One of the most frequent 
functions of small non-coding RNAs is the silencing of 
RNA expression by a base pairing interaction mechanism 
[10], which always involves a member of the Argonaute 
family that binds to the small non-coding RNAs. The PIWI 
protein subfamily of Argonaute proteins is composed of 
four members in humans: PIWIL1 (HIWI), PIWIL2 (HILI), 
PIWIL3 and PIWIL4 (HIWI2) [11]. The PIWI proteins 
bind to Piwi-interacting RNAs (piRNAs) [12], which are 
small, 24–32nt long, single-stranded RNAs. Until recently, 
piRNAs were believed to be expressed exclusively in the 
germ line [13, 14], but they are now known to be more 
universally expressed and have been detected in somatic 
and tumor cells [15–17]. Multiple functions have been 
associated with the PIWI/piRNA pathway, including 
the repression of transposons, which can multiply and 
move to new positions in the genome. By repressing 
transposons, the PIWI/piRNA pathway thus procures the 
genomic stability of germline cells [18]. piRNAs also target 
mRNAs, leading to their degradation, and are involved in 
epigenetic regulation in the nucleus of the cell [19, 20].
piRNA biogenesis is Dicer-independent and 
mediated by PIWI proteins [21]. Two main pathways 
of piRNA biogenesis have been described: the primary 
pathway and the secondary pathway (also known as the 
“ping-pong” amplification cycle). Little is known about 
the molecules that participate in piRNA biogenesis in 
humans, but PIWIL1 is known to act exclusively in the 
primary pathway and PIWIL4 in the secondary pathway, 
while PIWIL2 acts in both [14]. The primary pathway is 
believed to produce new piRNAs, while the secondary 
pathway is believed to be in charge of maintaining the 
total pool of active piRNAs in the cell [22–24].
In several cancer cell lines, PIWIL1 overexpression 
has been related to cell proliferation [25–27] and 
PIWIL2 overexpression to anti-apoptotic signaling and 
cell proliferation [28, 29]. Interestingly, PIWI genes are 
associated with stem cell self-renewal and are re-expressed 
in precancerous stem cells that have the potential for 
malignant differentiation [30, 31]. The first report of PIWI 
expression in tumor tissue was in seminomas, where 
PIWIL1 was detected in the tumor but not in normal tissue 
[22]. PIWIL1 overexpression has since been detected in 
sarcomas, where it drives tumorogenesis via increased 
global DNA methylation [32], in colorectal cancer [33], 
where it plays a role as a prognostic marker, and in other 
tumors (reviewed in [34]). However, the role of PIWI 
genes in NSCLC has not been studied.
We hypothesized that the PIWI/piRNA pathway 
may be an embryonic mechanism that is inactivated in 
adult differentiated lung cells and reactivated during 
tumorogenesis. To clarify this role of PIWI genes, we 
have examined their expression in human embryonic lungs 
(Figure 1A and 1B) and in paired tumor and normal tissue 
from surgically resected NSCLC patients and correlated 
our findings with patient outcome.
RESULTS
PIWI family expression during human lung 
embryogenesis
The expression of the PIWI genes PIWIL1–4 was 
assessed in human embryonic lung tissue from embryos 
of 6–13 weeks of development (Figure 1C–1F). The 
median 2-∆Ct values were 0.0084 and 0.0055 for PIWIL4 
and PIWIL2, respectively, in comparison with 0.00014 
and 0.000057 for PIWIL1 and PIWIL3, respectively. 
PIWIL4 thus had the highest expression levels. When 
we compared embryonic PIWI expression longitudinally 
from 6 to 13 weeks, significant changes in expression 
were observed only in PIWIL1 and PIWIL2 levels as 
the lung became more differentiated. PIWIL1 showed a 
significant reduction in overall levels from week 6 to 13 
(Figure 1C), while PIWIL2 showed a curved expression 
with an increase beginning at week 8, peaking at week 10, 
and decreasing to initial levels at week 13 (Figure 1D).
PIWI family expression in tumor and normal 
tissue samples and correlation with clinical 
characteristics
Seventy-one patients were included in the analysis. 
All patients had pathologically confirmed stage I–III 
NSCLC and Eastern Cooperative Oncology Group 
performance status 0–1 (Table 1). In tumor tissue, 
PIWIL1 expression was detected in eleven patients 
(15.5%), PIWIL2 in 66 (93%), PIWIL3 in five (7%) and 
PIWIL4 in 60 (84.5%). In normal tissue, only PIWIL2 and 
PIWIL4 were expressed, while PIWIL1 and PIWIL3 were 
not detected in any of the 71 normal tissues examined. 
Both PIWIL2 (Figure 2A) and PIWIL4 (Figure 2B) were 
significantly downregulated in tumor tissue compared to 
normal tissue ( p < 0.001).
PIWIL2 and PIWIL4 were downregulated in 
current and former smokers compared to never smokers 
( p = 0.01 and p = 0.003, respectively). PIWIL2 was also 
downregulated in patients with lymph node involvement 
(N0 vs N1/2; p = 0.038). No other correlation with clinical 
or molecular characteristics and PIWIL1–4 expression was 
observed.
PIWIL1 and PIWIL4 expression and clinical 
outcome
The 11 patients expressing PIWIL1 (PIWIL1 Ct < 
35 and β-actin < 35) had shorter TTR (22 vs 55 months; 
p = 0.006) and OS (32 vs 61 months; p = 0.0076) than those 
not expressing PIWIL1 (Figure 3A–3B). Using the cut-off 
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Figure 1: Images of the embryonic lung at (A) 7 weeks and (B) 13 weeks. Expression levels of (C) PIWIL1, (D) PIWIL2, 
(E) PIWIL3, and (F) PIWIL4 in the lung from week 6 to 13 of embryonic development.
Table 1: Patient characteristics
Characteristics Value N = 71 N (%) p-value*
TTR OS
Sex Male 60 (84.5)
Female 11 (15.5) 0.099 0.059
Age, yrs. Median (Range) 68 (46–83)
< = 65 31 (43.7)
> 65 40 (56.3) 0.183 0.122
ECOG PS 0 7 (9.9)
1 64 (90.1) 0.971 0.231
Stage I 44 (62)
II 17 (23.9)
III 10 (14.1) 0.055 0.008
(Continued )
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identified by the Maxstat package of R [35], we observed 
that patients with lower levels of PIWIL4 (PIWIL4 log10 
[2-∆Ct] ≤–2.31, percentile 21.5%, Figure 2) had shorter TTR 
(30 vs 56 months; p = 0.048) and OS (36 vs 62 months; 
p = 0.033) than those with high levels (Figure 3C–3D).
In the multivariate analyses, PIWIL1 expression 
emerged as an independent prognostic factor for TTR 
(OR, 2.892, 95% CI: 1.132–7.388; p = 0.026) and 
OS (OR, 2.833, 95% CI: 1.044–7.685; p = 0.041) 
(Table 2).
Characteristics Value N = 71 N (%) p-value*
TTR OS
Histology Adenocarcinoma 40 (56.3)
Squamous cell carcinoma 31 (43.7) 0.845 0.313
Type of surgery Lobectomy/Bilobectomy 60 (84.5)
Pneumonectomy 4 (5.6)
Atypical resection 7 (9.9) 0.830 0.491
Smoking history Current smoker 24 (33.8)
Former smoker 41 (57.7)
Never smoker 4 (5.6)
Unknown 2 (2.8) 0.315 0.109
Adjuvant treatment Yes 19 (26.8)
No 52 (73.2) 0.738 0.740
Relapse No 45 (63.4)
Yes 26 (36.6)
p53 mutations Yes 13 (18.3)
No 55 (77.5)
Unknown 3 (4.2) 0.181 0.905
K-ras mutations Yes 10 (14.1)
No 56 (78.9)
Unknown 5 (7) 0.533 0.391
*log-rank p-value for comparison of groups in univariate analysis.
TTR, time to relapse; OS, overall survival.
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Figure 2: Expression of (A) PIWIL2 and (B) PIWIL4 in paired normal (NT) and tumor tissue (TT) from patients with non-small-cell 
lung cancer.
Oncotarget31548www.impactjournals.com/oncotarget
A B
C D
Figure 3: (A) Time to relapse (TTR) and (B) overall survival (OS) according to PIWIL1 expression levels. (C) TTR and (D) OS according 
to PIWIL4 expression levels.
Table 2: Multivariate analyses
Time to Relapse Odds Ratio (95% CI) p-value
Male sex — 0.119
Stage I — 0.252
PIWIL1 expression 2.892 (1.132–7.388) 0.026
Low PIWIL4 expression levels — 0.089
Overall Survival Odds Ratio (95% CI) p-value
Male sex 6.668 (1.384–32.116) 0.018
Stage I 0.270 (0.091–0.802) 0.018
PIWIL1 expression 2.833 (1.044–7.685) 0.041
Low PIWIL4 expression levels — 0.220
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PIWIL1 analysis by immunohistochemistry
The study of PIWIL1 expression was validated at 
protein level by immunohistochemistry in 20 NSCLC 
cases (10 PIWIL1-positive and 10 PIWIL1-negative). 
The PIWIL1-positive cases showed faint cytoplasmic 
reactivity (Figure 4). Interestingly, the study by 
immunohistochemistry of embryonic samples showed that 
the expression of PIWIL1 was mainly found in the epithelial 
compartment of the embryonic lung (Figure 4A and 4B). 
Figure 4C and 4D show PIWIL1 expression in tumor tissue 
from a patient with squamous cell lung cancer. Figure 4E 
and 4F  show PIWIL1 expression in  a tumor tissue from a 
patient with lung adenocarcinoma.
A B 
C 
E 
D 
F 
Figure 4: Immunohistochemical analysis of PIWIL1 expression in (A, B) embryonic lung tissue, (C, D) tumor tissue from a patient 
with squamous cell lung cancer, (E, F) tumor tissue from a patient with lung adenocarcinoma. The images in the right column are a 
magnification of the images in the left column.
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PIWI family gene expression is partially 
regulated by methylation and correlates with 
overall methylation levels
Since PIWI genes had previously been described 
as regulated by methylation in human seminomas [36], 
we hypothesized that they could also be regulated by 
methylation in NSCLC. We treated two NSCLC cell 
lines A549 and H23 with the demethylating agent 5-Aza-
dC and analyzed the expression of the four PIWI genes. 
A dose-dependent increase in the expression levels of 
the four genes after 5-Aza-dC treatment was observed 
(Figure 5A). We then focused further analyses on PIWIL1. 
We performed bisulfite sequencing analysis of the 43 CpG 
island located in its promoter region in 4 samples (one 
8-week embryonic lung, one 13-week embryonic lung, 
one PIWIL1-positive tumor and one PIWIL1-negative 
tumor) (Figure 5B). The 8-week embryonic lung showed 
the highest unmethylation level (20.5%). The PIWIL1-
positive case showed higher unmethylation (17.2%) than 
the PIWIL1-negative case (6.1%) (Figure 5B).
Finally, since epigenetic functions have been 
associated with piRNAs, we examined the relation 
between the expression of the PIWI genes and overall 
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Figure 5: Study of the methylation of PIWI genes in lung cancer. (A) 5-Aza-dC treatment of H23 and A549 lung cancer cell lines 
showed an increase of the expression levels of the four PIWI genes. (B) Schematic representation of the PIWIL1 gene showing the presence 
of a CpG island close to the first exon of PIWIL1 gene. The bisulfite sequencing analysis of the 43 CpG island showed differences between 
a PIWIL1-positive and a PIWIL1-negative case.
Oncotarget31551www.impactjournals.com/oncotarget
changes in methylation levels in tumor samples. We 
observed a positive correlation of PIWIL4 levels with 
overall methylation (r = 0.267, p = 0.044).
Enriched gene signatures associated with 
PIWIL1 expression
Since PIWIL1 was highly expressed during early lung 
development and PIWIL1 expression in tumor tissue was a 
marker of poor prognosis, we postulated that its expression 
could be associated with stem-cell characteristics. We 
therefore compared in  silico the expression patterns 
associated with PIWIL1-positive patients vs PIWIL1-
negative patients. Using the public data available in GEO, 
we used the data from expression arrays performed in 58 
NSCLC cases (GSE10245; PMID: 18486272). In these 
patients, we studied the expression of PIWIL1 gene and 
identified four patients expressing PIWIL1 (Figure 6A). 
We then compared gene expression between these four 
patients and the 54 PIWIL1-negative patients and were 
able to identify a 451-gene signature (72 upregulated and 
379 downregulated) associated with PIWIL1 expression 
(Supplementary Table 1). To study the functional relevance 
of this signature, we performed a Gene Set Enrichment 
Analysis (GSEA). GSEA identified several gene signatures 
(Supplementary Figure 1), including a gene signature 
associated with stem cells (“Wong_Adult_Tissue_Stem_
Module”) (Figure 6B) [37]. Figure 6C displays all the 
genes included in the GSEA analysis after the filtering 
performed by the program; significant differences were 
observed between the PIWIL1-positive and PIWIL1-
negative group.
DISCUSSION
In the present study, we have examined whether 
the re-activation of the PIWI/piRNA pathway in tumor 
tissue influences patient outcome in NSCLC. The PIWI/
piRNA pathway was until recently thought to be active 
exclusively in germinal cells and in the first stages 
of embryonic development [14]. However, we have 
shown that PIWI expression can be detected during lung 
organogenesis, with a distinct expression pattern for each 
PIWI gene. Moreover, some PIWI genes can be detected in 
tumor and normal tissue – again with distinct expression 
patterns.
In piRNA biogenesis, we can distinguish two 
main pathways: the primary pathway and the secondary 
pathway. PIWIL1 participates exclusively in the primary 
pathway. The expression pattern of PIWIL1 indicates that 
while the primary pathway is very active during the early 
stages of lung embryogenesis, this pathway becomes 
downregulated during the differentiation of the embryonic 
and fetal lung and is finally inactivated in normal adult 
lung tissue. Interestingly, this pathway is reactivated in 
some patients, where it is a marker of poor prognosis. It 
has been shown in seminoma patients that this inactivation 
may be mediated by methylation [36]. To corroborate if 
this methylation-mediated inactivation would hold true in 
NSCLC, we treated two NSCLC cell lines with 5-Aza-dC, 
which led to the re-expression of all PIWI family members. 
Moreover, we analyzed a PIWIL1-positive and a PIWIL1-
negative tumor sample by bisulfite sequencing and found 
differences in the degree of methylation between the two 
samples. These results lead us to speculate that in lung 
cancer, PIWIL1 inactivation may well be mediated in part 
by methylation of its promoter region. Other mechanisms 
have also been shown to affect PIWIL1 expression. 
Reeves and coworkers found that PIWIL1 expression was 
higher in NSCLC cell lines (A549 and NCI-H1299) than 
in normal lung epithelial cells (CRL-9482) and that the 
expression of PIWIL1 could be activated by the oncogene 
RASSF1C [38].
In the present study, we have shown that the re-
activation of PIWIL1 in tumors is associated with a stem-
cell expression signature. Liang et al. [39] have recently 
reported that PIWIL1 is essential to the maintenance of 
lung cancer stem cell populations. Knockdown of PIWIL1 
compromised sphere formation ability in the stem cell 
population SSClo Aldebr and in  vivo tumor growth in 
a nude mice model [39]. In a previous study, the same 
group showed that PIWIL1 gene silencing decreased 
proliferation and promoted apoptosis in lung cancer stem 
cells [40]. Although the prognostic significance of PIWIL1 
expression has not previously been examined in NSCLC, 
it has been associated with poor outcome in other tumors, 
including glioma [26], pancreatic cancer [41], colorectal 
cancer [42], esophageal cancer [43], liver cancer [44], 
gastric cancer [45], and sarcomas [25, 46]. Furthermore, 
in glioma [47], breast cancer [48] and sarcomas [49], in 
vitro studies have shown that the suppression of PIWIL1 
caused inhibition of cell growth by different mechanisms. 
Our finding that PIWIL1 expression was related to shorter 
TTR ( p = 0.006) and OS ( p = 0.0076) is along the same 
lines as these studies in other tumors and indicate that 
PIWIL1 re-expression could be a useful prognostic and 
therapeutic marker. Moreover, PIWIL1 protein levels 
can be easily detected in the pathology laboratory by 
immunohistochemistry.
PIWIL2 and PIWIL4 are active in the secondary 
pathway of piRNA biogenesis, where they participate 
in the “ping-pong” amplification cycle. PIWIL2 and 
PIWIL4 were both expressed in all samples – both in 
the embryonic and the adult normal and tumor tissue. In 
fact, during lung organogenesis (6–13 weeks), PIWIL2 
and PIWIL4 expression is higher than that of PIWIL1 or 
PIWIL3. PIWIL4 expression remained high throughout 
the 6–13 weeks of development. In contrast, PIWIL2 
expression increased significantly during the transition 
from the embryonic to the pseudoglandular stage of 
lung development, when there is a high rate of cell 
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proliferation in order to produce the branching of the 
fetal lung. At embryonic weeks 6–8, endodermic buds 
appear, surrounded by mesenchymal mesodermic cells. At 
week 10, the endodermic cells acquire the characteristics 
of pseudostratified epithelium, and branching occurs. At 
week 12, branching morphogenesis continues and the 
bronchial lumen can be observed, covered by a cubic 
endodermic epithelium [7]. The changes observed in 
PIWIL2 expression and the consistently high expression 
of PIWIL4 during this time could be related to this high 
rate of proliferation, highlighting the importance of the 
secondary piRNA pathway during this transition phase. 
Both PIWIL2 and PIWIL4 were also expressed in tumor 
and normal tissue, indicating that the secondary pathway 
is not inactivated in adult tissue. Interestingly, PIWIL2 
and PIWIL4 were expressed at significantly lower 
levels in tumor than in paired normal tissue ( p < 0.001). 
Importantly, patients with lower levels of PIWIL4 had 
shorter TTR ( p = 0.048) and OS ( p = 0.033).
It has been postulated that the secondary pathway 
is in charge of the maintenance of the pool of piRNAs of 
the cell, especially those targeting transposons [14]. This 
would match with the fact that PIWIL2 and PIWIL4 were 
detected in all our samples. Moreover, the downregulation 
of these genes in tumor samples could be related to an 
increase of transposon activities, resulting in genomic 
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Figure 6: In silico analysis using GEO public data (GSE10245) to identify gene expression signatures associated with 
PIWIL1 expression. (A) Classification of patients according to PIWIL1 expression. Four patients were classified as PIWIL1-positive. 
(B) Enrichment plot showing that the gene expression signature associated with PIWIL1-positive patients is enriched in the Wong_Adult_
Tissue_Stem_Module. (C) Heat map of genes used by GSEA after filtering to perform the analysis. The heat map shows significant 
differences in the gene expression signature between PIWIL1-positive and PIWIL1-negative patients.
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instability [50]. One of the mechanisms used by the 
piRNAs to silence transposons is DNA methylation [51]. 
It has been shown that PIWIL4 can modulate chromatin 
modifications through methylation of H3K9, specifically 
in the p16Ink4a locus [52]. In our study, we have observed 
a positive correlation between PIWIL4 levels and overall 
methylation. However, since the overall methylation levels 
were quantified using an ELISA method, it is not clear if 
the overall methylation corresponds to transposon regions 
or other transposable elements regulated by piRNAs. This 
interesting question warrants further study with more 
complex techniques.
In summary, we have examined the expression of 
PIWI genes in order to determine the activity and potential 
prognostic role of the PIWI/piRNA pathway in NSCLC. 
PIWIL1 participates in the primary pathway and PIWIL2 
and PIWIL4 in the secondary pathway, both of which are 
active in NSCLC. The re-expression of the PIWIL1 gene, 
which can be confirmed by immunohistochemistry, is 
related to poor prognosis and is associated with a stem-
cell signature. The downregulation of PIWIL4 is also 
related to poor prognosis and is associated with lower 
methylation. Further investigation in a larger cohort of 
patients is warranted to validate these findings and to 
examine potential diagnostic and therapeutic approaches.
MATERIALS AND METHODS
Study population
Seventy-one fresh tumor samples and 71 paired 
normal tissue samples from NSCLC patients who 
underwent complete surgical resection in our institution 
were prospectively collected between June 2007 and 
March 2011. Immediately after surgery, samples were 
labelled, frozen at –80°C and kept for further processing. 
Approval for the study was obtained from the Institutional 
Review Board of the Hospital Clinic of Barcelona, 
Spain. Written informed consent was obtained from each 
participant in accordance with the Declaration of Helsinki.
Twenty clinically aborted embryos and fetuses 
were donated with written informed consent to the Body 
Donation Service of the Human Anatomy and Embryology 
Department of the School of Medicine of University of 
Barcelona for morphological and molecular studies. The 
samples included lungs from the 6th to the 13th week of 
development. Lung samples were obtained under control 
of an Olympus stereo microscope SZ61. Samples for RNA 
extraction were frozen in liquid nitrogen and stored at 
–80°C until analyzed.
RNA extraction and mRNA quantification
Total RNA was extracted from tumor and normal 
frozen tissue using Trizol (Life Technologies, Foster 
City, CA) according to the manufacturer’s protocol. RNA 
from samples was quantified using a NanoDrop 1000 
Spectrophotometer.
cDNA was synthesized from total RNA using the 
High Capacity cDNA Reverse Transcription Kit (Life 
Technologies) as per the manufacturer’s protocol. TaqMan 
expression assays to determine RNA levels of PIWIL1 
(Hs01041737_m1), PIWIL2 (Hs00216263_m1), PIWIL3 
(Hs00908825_m1), and PIWIL4 (Hs00381509_m1) 
were supplied by Life Technologies. β-actin was used as 
housekeeping gene. RT-QPCR was performed in a total 
volume of 20 μl in the ABI Prism 7500 Real Time PCR 
System (Life Technologies). All samples for each gene 
were run in triplicate for 40 cycles using the following 
master mix and thermal cycler conditions: 10 μl of the 
TaqMan universal PCR master mix, 1 μl of the primers 
and probes, 2 μl of the cDNA and 7 μl of the RNAse-free 
water; about 2 min 50°C, 10 min 95°C, 15 s 95°C and 
1 min 60°C. Fluorescent emission data were captured, and 
mRNA concentrations were quantified by using the critical 
threshold value and 2–ΔΔCt method.
Immunohistochemistry
Five-μm-thick transverse sections of formalin-
fixed paraffin-embedded (FFPE) tissues were serially 
cut and mounted onto Dako Silanized Slides (Dako, 
Glostrup, Denmark). The immunohistochemical assay 
was performed as previously described [53] using rabbit 
polyclonal antibodies anti-human PIWIL1 (ab85125; 
Abcam, Cambridge, UK).
Global methylation quantification
Global methylation was determined as previously 
described [54, 55] in total DNA of all samples by a 
specific ELISA assay (MethylFlash™ Methylated DNA 
Quantification Kit, Epigentek, Farmingdale, NY), which is 
capable of recognizing the DNA methylated fraction. This 
test uses a monoclonal antibody against 5-methylcytosine 
(5-mC) to obtain the percentage of 5-mC in total DNA. 
The procedure was performed according to manufacturer’s 
protocol.
PIWIL1-associated gene expression signature
Using arrays obtained from the Gene Expression 
Omnibus database (GSE10245), we examined 
the gene expression associated with patients who 
expressed PIWIL1. Raw files (.cel) were normalized 
using R statistical package (Institute for Statistics and 
Mathematics, Vienna, AU) and Bioconductor (www.
bioconductor.org). The raw data was normalized using 
the rma method from the affy package (Bioconductor). 
After normalization, we obtained the expression data 
of PIWIL1 (probe: 214868_at). The samples that had 
higher expression than the mean and standard deviation 
of the population were classified as PIWIL1-positive. 
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A t-test based on permutations was used to identify 
genes differentially expressed between patients with high 
and low PIWIL1 expression. The Gene Set Enrichment 
Analysis (GSEA v.2.1.0) program from “The Broad 
Institute” [56] was used to identify the enriched gene 
signatures associated with PIWIL1 expression.
Cell culture and treatment
Two NSCLC cell lines, H23 (American Type 
Culture Collection) and A549 (DSMZ - the German 
Resource Centre for Biological Material) were used. H23 
and A549 cells were cultured in RPMI 1640 (Invitrogen) 
and DMEM (Invitrogen) respectively, containing 10% 
fetal calf serum (Invitrogen).
For methylation analysis, both cell lines (5 × 105 
cells) were plated 24 h prior to treatment. Cells were 
then treated daily with 1 μM/3 μM/10 μM 5-Aza-2-
deoxycytidine (5-Aza-dC) during 6 days; on the 7th day, 
the cells were harvested and gene expression was assessed.
Bisulfite sequencing
The methylation status of PIWIL1 was studied 
by bisulfite sequencing. Following sodium bisulfite 
treatment using Methylamp DNA Modification Kit 
(Epigentek, Farmingdale, NY), the CpG island located 
in the 5′ region of PIWIL1 gene (UCSC GRCh37/hg19: 
chr12:130822361–130822696) was PCR amplified using 
Forward 5′-GGGGTTTTTTTGGTTT-3′ and Reverse 
5′-CACCTAACACCTCAACCTAACC-3′ primers. PCR 
products were subcloned using the TOPO TA Cloning 
kit (Invitrogen, Life Technologies) into pCR2.1-Topo 
TA Vector plasmid and 5 candidate plasmid clones were 
sequenced. The resulting sequences were analyzed using 
BISMA [57].
Statistical analyses
The primary endpoints of the study were to 
assess time to relapse (TTR) and overall survival (OS), 
calculated from the time of surgical treatment to the 
date of relapse or death from any cause, respectively. 
TTR and OS were calculated using the Kaplan–Meier 
method and compared using the log-rank test. Optimal 
cut-off points of gene expression data for TTR were 
assessed by means of maximally selected log-rank 
statistics [24] using the Maxstat package (version 2.8.1; 
R statistical package) and confirmed by the Kaplan–
Meier test. All variables with a p-value ≤ 0.1 in the 
univariate analysis were included in a Cox multivariate 
analysis in order to calculate the independent odds 
ratios (ORs) for TTR and OS. All statistical analyses 
were performed with PASW Statistics 18 (SPSS Inc., 
Chicago, IL, USA) and R version 2.13. Statistical 
significance was set at p ≤ 0.05.
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